Story · Medicine & Biotech
Katy Beckermann: ENZARAD Finds No Overall Metastasis-Free Survival Benefit With Enzalutamide
1 outlet · first reported by OncoDaily on
Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X: “High-risk prostate cancer on RT plus 2 yrs of ADT: 2 yrs of enzalutamide did no (OncoDaily)
Coverage, in order
-
Katy Beckermann: ENZARAD Finds No Overall Metastasis-Free Survival Benefit With EnzalutamideKaty Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X: “High-risk prostate cancer on RT plus 2 yrs of ADT: 2 yrs of enzalutamide did no
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.